Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Alzheimer's education (no specific bill); 340B (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074, S. 539); Eliminating Disparities in Diabetes Prevention, Access and Care Act (H.R. 3322); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill); DISARM (H.R. 4187)
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MERCK & CO INC via MERCK & CO, INC.
2014 · second_quarter · Q2
Trans-Pacific Partnership (no specific bill), biologic data exclusivity (no specific bill), trade promotion authority (no specific bill), treatment of intellectual property in India (no specific bill), Playing Fair on Trade and Innovation Act (H.R. 3167), additives in beef cattle (no specific bill), trade adjustment assistance (no specific bill), international trade barriers for beta-agonists (no specific bill)
Patent reform (H.R. 3309, S.1720)
Source: Senate LDA
Alzheimer's education (no specific bill), 340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), general pharmaceutical industry education, OTC medicines - dextromethorpan and pseudoephedrine (no specific bill).
Trans-Pacific Partnership (no specific bill), biologic data exclusivity (no specific bill), trade promotion authority (no specific bill), treatment of intellectual property in India (no specific bill), Playing Fair on Trade and Innovation Act (H.R. 3167), additives in beef cattle (no specific bill), trade adjustment assistance (no specific bill), international trade barriers for beta-agonists (no specific bill)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); Playing Fair on Trade and Innovation Act (HR 3167); additives in beef cattle (no specific bill); trade ajustment assistance (no specific bill); international trade barriers for beta-agonists (no specific bill)
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Alzheimer's education (no specific bill), 340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), general pharmaceutical industry education, OTC medicines - dextromethorpan and pseudoephedrine (no specific bill).
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Alzheimer's education (no specific bill); 340B (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074, S. 539); Eliminating Disparities in Diabetes Prevention, Access and Care Act (H.R. 3322); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill); DISARM (H.R. 4187)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351); sustainable growth rate (H.R. 4302)
Alzheimer's education (no specific bill), 340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), general pharmaceutical industry education, OTC medicines - dextromethorpan and pseudoephedrine (no specific bill).
Alzheimer's education (no specific bill); 340B (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074, S. 539); Eliminating Disparities in Diabetes Prevention, Access and Care Act (H.R. 3322); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill); DISARM (H.R. 4187)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351); sustainable growth rate (H.R. 4302)
Comprehensive tax reform (no specific bill), transfer pricing of intangibles (no specific bill), territorial tax system (no specific bill), deferral of taxation of foreign earned income (no specific bill), tax base erosion (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill)
Patent Transparency and Improvements Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Patent reform (H.R. 3309, S.1720)
Patent Transparency and Improvements Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Patent reform (H.R. 3309, S. 1720 )
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351); sustainable growth rate (H.R. 4302)
Alzheimer's education (no specific bill); 340B (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074, S. 539); Eliminating Disparities in Diabetes Prevention, Access and Care Act (H.R. 3322); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill); DISARM (H.R. 4187)
Alzheimer's education (no specific bill), 340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), general pharmaceutical industry education, OTC medicines - dextromethorpan and pseudoephedrine (no specific bill).
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Alzheimer's education (no specific bill); 340b (no specific bill); maternal health education (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill)
Safeguarding America's Pharmaceuticals Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 1919, S. 959, S. 957)
Safeguarding America's Pharmaceuticals Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 1919, S. 959, S. 957)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); Playing Fair on Trade and Innovation Act (HR 3167); additives in beef cattle (no specific bill)
Drug Quality and Security Act (HR 3204)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Deficit reduction (no specific bill); ADAP funding (no specific bill); Sequestration of FDA user fees (S. 1413, H.R.2775)
Deficit reduction (no specific bill); ADAP funding (no specific bill); Sequestration of FDA user fees (S. 1413, H.R.2775)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Supply chain safety (H.R. 1919, S. 959, S. 957)
Supply chain safety (H.R. 1919, S. 959, S. 957)
Pharmaceutical Quality, Security, and Accountability Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 1919, S. 959, S. 957)
Pharmaceutical Quality, Security, and Accountability Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 1919, S. 959, S. 957)
Generating Antibiotic Incentives Now Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (H.R. 3381); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Generating Antibiotic Incentives Now Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Generating Antibiotic Incentives Now Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Prescription Drug User Fee Act (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill)
Preserving Access to Life-Saving Medications Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (no specific bill); pharmaceutical shortages (H.R. 2245, S. 296)
Preserving Access to Life-Saving Medications Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187)
Preserving Access to Life-Saving Medications Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Preserving Access to Life-Saving Medications Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Hepatitis C education (H.R. 3381); Alzheimer's education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (H.R. 3381); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Medicare Decisions Accountability Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Medicare Decisions Accountability Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Medicare Decisions Accountability Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Medicare Decisions Accountability Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Food and Drug Administration Reform Act of 2012
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Food and Drug Administration Reform Act of 2012
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187)
Food and Drug Administration Reform Act of 2012
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (H.R. 3381); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Food and Drug Administration Reform Act of 2012
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Food and Drug Administration Reform Act of 2012
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Generating Antibiotic Incentives Now Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Prescription Drug User Fee Act reauthorization (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); improvements to immunizations (no specific bills); health literacy (no specific bills); adherence (no specific bill)
Generating Antibiotic Incentives Now Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Prescription Drug User Fee Act (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); pharmaceutical shortages (S. 296, H.R. 2245)
Generating Antibiotic Incentives Now Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Prescription Drug User Fee Act (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and devlopment (H.R. 2182); hepatitis C education (no specific bill); pharmaceutical shortages (S. 296, HR. 2245)
Preserving Access to Life-Saving Medications Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Prescription Drug User Fee Act (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); pharmaceutical shortages (S. 296, H.R. 2245)
Preserving Access to Life-Saving Medications Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Prescription Drug User Fee Act (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and devlopment (H.R. 2182); hepatitis C education (no specific bill); pharmaceutical shortages (S. 296, HR. 2245)
United States-Korea Free Trade Agreement Implementation Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Korea Free Trade Agreement (H.R. 3080); TranPacific Partnership
Medicare Decisions Accountability Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Medicare Decisions Accountability Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Medicare Decisions Accountability Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Medicare Decisions Accountability Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
American Research and Competitiveness Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of the R&D tax credit (H.R. 942); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill).
American Research and Competitiveness Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of teh R&D tax credit (H.R. 942); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill).
American Research and Competitiveness Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of the R&D tax credit (H.R. 942; S 1577); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill).
American Research and Competitiveness Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of the R&D tax credit (H.R. 942); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income.
America's Affordable Health Choices Act of 2009
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
RX drug importation into the US, other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Promote public/private partnerships for comparative effectiveness assessment (S. 1213). Physician Payments Sunshine Act of 2009 (S. 301). Health care reform; increasing coverage of uninsured; coverage of preventative services, including immunizations; expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization; maintaining market-based, private sector health care delivery system. (H.R. 3200; S. 1679; S. 1796; H.R. 3590; H.R. 4872)
America's Affordable Health Choices Act of 2009
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Efforts to amend the Medicare Modernization Act to impose government price controls on prescription drugs (no specific legislation); efforts to ensure appropriate access to vaccines under Medicare (H.R. 3200; S. 1796; H.R. 3590); Expansion of, or increase in, Medicaid rebates (H.R. 3200; S. 1796; H.R. 3590; H.R. 4872)
America's Affordable Health Choices Act of 2009
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Efforts to amend the Medicare Modernization Act to impose government price controls on prescription drugs (no specific legislation). Efforts to ensure appropriate access to vaccines under Medicare (H.R. 3200; S. 1796; H.R. 3590). Expansion of or increase in Medicaid rebate (H.R. 3200; S. 1796;H.R. 3590; H.R. 4872).
America's Affordable Health Choices Act of 2009
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Rx drug importation into the US, other than by drug manufacturer (no specific bill); requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill); promote public/private partnerships for comparative effectiveness assessments (S. 1213); Physician Payments Sunshine Act of 2009 (S. 301); health care reform; increasing coverage of uninsured; coverage of preventative services; including immunizations; expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization; maintaining market-based, private sector health care delivery system (H.R. 3200; S. 1679; S. 1796; H.R. 3590; H.R. 4872)
Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Rx drug importation into the U.S., other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Implementation of comparative effectiveness provisions of health care reform bill (H.R. 3590). Awareness and treatment of viral hepatitis (S. Res. 531; H.R. 3974). Expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization.
Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Rx drug importation into the U.S., other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Implementation of comparative effectiveness provisions of health care reform bill (H.R. 3590). Awareness and treatment of viral hepatitis (S. Res. 531; H.R. 3974). Expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization.
Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Rx drug importation into the U.S., other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Implementation of comparative effectiveness provisions of health care reform bill (H.R. 3590). Awareness and treatment of viral hepatitis (S. Res. 531; H.R. 3974). Expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization.
Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Rx drug importation into the U.S., other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Implementation of comparative effectiveness provisions of health care reform bill (H.R. 3590). Awareness and treatment of viral hepatitis (S. Res. 531; H.R. 3974). Expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization. Implementation of the Independent Payment Advisory Board provisions of health care reform bill (H.R. 3590). Reauthorization of the Prescription Drug User Fee Act (no specific bill).
To amend the Internal Revenue Code of 1986 to extend the research credit through 2010 and to increase and make permanent the alternative simplified research credit.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Deferral of taxation of foreign earned income and corporate taxation (no specific legislation). Renewal and expansion of the R&D tax credit (H.R. 422; S. 1203)
To amend the Internal Revenue Code of 1986 to extend the research credit through 2010 and to increase and make permanent the alternative simplified research credit.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Deferral of taxation of foreign earned income and corporate taxation (no specific legislation). Renewal and expansion of the R&D tax credit (Support H.R. 422; S. 1203)
To amend the Internal Revenue Code of 1986 to extend the research credit through 2010 and to increase and make permanent the alternative simplified research credit.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Deferral of taxation of foreign earned income and corporate taxation (no specific legislation); renewal and expansion of the R&D tax credit (H.R. 422; S. 1203)
To amend the Internal Revenue Code of 1986 to extend the research credit through 2010 and to increase and make permanent the alternative simplified research credit.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Deferral of taxation of foreign earned income and corporate taxation (no specific legislation). Renewal and expansion of the R&D tax credit (H.R. 422; S. 1203)
To amend the Internal Revenue Code of 1986 to extend the research credit through 2010 and to increase and make permanent the alternative simplified research credit.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Deferral of taxation of foreign earned income and transfer pricing of intangibles (no specific legislation). Renewal and expansion of the R&D tax credit (H.R. 422; S. 1203) Miscellaneous corporate tax provisions (H.R. 5893)
To amend the Internal Revenue Code of 1986 to extend the research credit through 2010 and to increase and make permanent the alternative simplified research credit.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Deferral of taxation of foreign earned income and corporate taxation (no specific legislation). Renewal and expansion of the R&D tax credit (H.R. 422; S. 1203)
Investing in American Jobs and Closing Tax Loopholes Act of 2010
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Deferral of taxation of foreign earned income and transfer pricing of intangibles (no specific legislation). Renewal and expansion of the R&D tax credit (H.R. 422; S. 1203) Miscellaneous corporate tax provisions (H.R. 5893)
Deferral of taxation of foreign earned income and transfer pricing of intangibles (no specific legislation). Renewal and expansion of the R&D tax credit (H.R. 422; S. 1203) Miscellaneous corporate tax provisions (H.R. 5893)
Deferral of taxation of foreign earned income and corporate taxation (no specific legislation). Renewal and expansion of the R&D tax credit (Support H.R. 422; S. 1203)
Deferral of taxation of foreign earned income and corporate taxation (no specific legislation). Renewal and expansion of the R&D tax credit (H.R. 422; S. 1203)
Deferral of taxation of foreign earned income and corporate taxation (no specific legislation). Renewal and expansion of the R&D tax credit (H.R. 422; S. 1203)
Deferral of taxation of foreign earned income and corporate taxation (no specific legislation). Renewal and expansion of the R&D tax credit (H.R. 422; S. 1203)
Deferral of taxation of foreign earned income and corporate taxation (no specific legislation); renewal and expansion of the R&D tax credit (H.R. 422; S. 1203)
Patient-Centered Outcomes Research Act of 2009
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
RX drug importation into the US, other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Promote public/private partnerships for comparative effectiveness assessment (S. 1213). Physician Payments Sunshine Act of 2009 (S. 301). Health care reform; increasing coverage of uninsured; coverage of preventative services, including immunizations; expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization; maintaining market-based, private sector health care delivery system. (H.R. 3200; S. 1679; S. 1796; H.R. 3590; H.R. 4872)
Patient-Centered Outcomes Research Act of 2009
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Rx drug importation into the US, other than by drug manufacturer (no specific bill); requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill); promote public/private partnerships for comparative effectiveness assessments (S. 1213); Physician Payments Sunshine Act of 2009 (S. 301); health care reform; increasing coverage of uninsured; coverage of preventative services; including immunizations; expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization; maintaining market-based, private sector health care delivery system (H.R. 3200; S. 1679; S. 1796; H.R. 3590; H.R. 4872)
RX drug importation into the US, other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Promote public/private partnerships for comparative effectiveness assessment (S. 1213). Physician Payments Sunshine Act of 2009 (S. 301). Health care reform; increasing coverage of uninsured; coverage of preventative services, including immunizations; expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization; maintaining market-based, private sector health care delivery system. (H.R. 3200; S. 1679; S. 1796; H.R. 3590; H.R. 4872)
Rx drug importation into the US, other than by drug manufacturer (no specific bill); requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill); promote public/private partnerships for comparative effectiveness assessments (S. 1213); Physician Payments Sunshine Act of 2009 (S. 301); health care reform; increasing coverage of uninsured; coverage of preventative services; including immunizations; expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization; maintaining market-based, private sector health care delivery system (H.R. 3200; S. 1679; S. 1796; H.R. 3590; H.R. 4872)
Comprehensive tax reform (no specific bill), transfer pricing of intangibles (no specific bill), territorial tax system (no specific bill), deferral of taxation of foreign earned income (no specific bill), tax base erosion (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill)
Deficit reduction (no specific bill)
Alzheimer's education (no specific bill), 340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), general pharmaceutical industry education, OTC medicines - dextromethorpan and pseudoephedrine (no specific bill).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2014 · first_quarter · Q1
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351); sustainable growth rate (H.R. 4302)
Alzheimer's education (no specific bill); 340B (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074, S. 539); Eliminating Disparities in Diabetes Prevention, Access and Care Act (H.R. 3322); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill); DISARM (H.R. 4187)
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill); R&D tax credit (no specific bill).
Patent reform (H.R. 3309, S. 1720 )
Deficit reduction (no specific bill); ADAP funding (no specific bill); omnibus appropriations...
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); Playing Fair on Trade and Innovation Act (HR 3167); additives in beef cattle (no specific bill); trade ajustment assistance (no specific bill); international trade barriers for beta-agonists (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2013 · fourth_quarter · Q4
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Drug Quality and Security Act (HR 3204)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); Playing Fair on Trade and Innovation Act (HR 3167); additives in beef cattle (no specific bill)
Deficit reduction (no specific bill); ADAP funding (no specific bill); Sequestration of FDA user fees (S. 1413, H.R.2775)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Patent reform (H.R. 3309)
Alzheimer's education (no specific bill); 340b (no specific bill); maternal health education (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
MERCK & CO INC via MERCK & CO, INC.
2013 · first_quarter · 1A
Deficit reduction (no specific bill); ADAP funding (no specific bill)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Patent settlements (no specific bill)
Alzheimer's education (no specific bill); 340b (no specific bill); hepatitis C education (no specific bill).
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Supply chain safety (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2013 · third_quarter · Q3
Access to over-the-counter medications (no specific bill); compounding (no specific bill)
Alzheimer's education (no specific bill); 340b (no specific bill); maternal health education (no specific bill).
Supply chain safety (H.R. 1919, S. 959, S. 957)
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Deficit reduction (no specific bill); ADAP funding (no specific bill); Sequestration of FDA user fees (S. 1413, H.R.2775)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); additives in beef cattle (no specific bill); treatment of intellectual property in India
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
MERCK & CO INC via MERCK & CO, INC.
2013 · second_quarter · Q2
Supply chain safety (H.R. 1919, S. 959, S. 957)
Patent settlements (no specific bill)
Alzheimer's education (no specific bill); 340b (no specific bill); maternal health education (no specific bill).
MERCK & CO INC via MERCK & CO, INC.
2013 · first_quarter · Q1
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Alzheimer's education (no specific bill); 340b (no specific bill); hepatitis C education (no specific bill).
MERCK & CO INC via MERCK & CO, INC.
2012 · fourth_quarter · Q4
Deficit reduction (no specific bill); ADAP funding (no specific bill)
Hepatitis C education (H.R. 3381); Alzheimer's education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Great Apes (S. 810)
MERCK & CO INC via MERCK & CO, INC.
2012 · third_quarter · Q3
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (H.R. 3381); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Deficit reduction (no specific bill); ADAP funding (no specific bill)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
MERCK & CO INC via MERCK & CO, INC.
2012 · second_quarter · Q2
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); permanent normal trade relations with Russia (no specific bill); non-tariff trade barriers on U.S. beef (no specific bill)
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
MERCK & CO INC via MERCK & CO, INC.
2012 · first_quarter · Q1
Supply chain safety (no specific bill); pharmaceutical shortages (H.R. 2245, S. 296)
Comprehensive Tax Reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
MERCK & CO INC via MERCK & CO, INC.
2011 · fourth_quarter · Q4
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Korea Free Trade Agreement (H.R. 3080); TranPacific Partnership
Deficit Reduction (no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2011 · third_quarter · Q3
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Prescription Drug User Fee Act (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); pharmaceutical shortages (S. 296, H.R. 2245)
Patent Reform (H.R. 1249)
MERCK & CO INC via MERCK & CO, INC.
2011 · second_quarter · Q2
Deficit reduction (no specific bill); WTO Cotton agreement (H.R. 2112); FDA funding (H.R. 2112); ADAP funding (no specific bill)
Prescription Drug User Fee Act (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and devlopment (H.R. 2182); hepatitis C education (no specific bill); pharmaceutical shortages (S. 296, HR. 2245)
Patent Reform (H.R. 1249)
MERCK & CO INC via MERCK & CO, INC.
2011 · first_quarter · Q1
Prescription Drug User Fee Act (no specific bill); importation of pharmaceuticals (no specific bill).
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of the R&D tax credit (H.R. 942); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income.
MERCK & CO INC via MERCK & CO, INC.
2010 · first_quarter · 1A
Rx drug importation into the US, other than by drug manufacturer (no specific bill); requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill); promote public/private partnerships for comparative effectiveness assessments (S. 1213); Physician Payments Sunshine Act of 2009 (S. 301); health care reform; increasing coverage of uninsured; coverage of preventative services; including immunizations; expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization; maintaining market-based, private sector health care delivery system (H.R. 3200; S. 1679; S. 1796; H.R. 3590; H.R. 4872)
Efforts to amend the Medicare Modernization Act to impose government price controls on prescription drugs (no specific legislation); efforts to ensure appropriate access to vaccines under Medicare (H.R. 3200; S. 1796; H.R. 3590); Expansion of, or increase in, Medicaid rebates (H.R. 3200; S. 1796; H.R. 3590; H.R. 4872)
MERCK & CO INC via MERCK & CO, INC.
2010 · fourth_quarter · Q4
Renewal and expansion of the R&D tax credit, miscellaneous corporate tax provisions (H.R. 4853)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2010 · third_quarter · Q3
Increased funding for CDC's National Immunization Program (Sec. 317 Program); increased funding for the AIDS Drug Assistance Program and for the Division of Viral Hepatitis at CDC (FY 11 Budget and Labor-Health & Human Services Appropriations bill)
Deferral of taxation of foreign earned income and transfer pricing of intangibles (no specific legislation). Renewal and expansion of the R&D tax credit (H.R. 422; S. 1203) Miscellaneous corporate tax provisions (H.R. 5893)
Rx drug importation into the U.S., other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Implementation of comparative effectiveness provisions of health care reform bill (H.R. 3590). Awareness and treatment of viral hepatitis (S. Res. 531; H.R. 3974). Expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization. Implementation of the Independent Payment Advisory Board provisions of health care reform bill (H.R. 3590). Reauthorization of the Prescription Drug User Fee Act (no specific bill).
MERCK & CO INC via MERCK & CO, INC.
2010 · second_quarter · 2A
Change in formula for Average Manufacturers' Price for Medicaid. Efforts to amend the Medicare Modernization Act to impose government price controls on prescription drugs and to ensure appropriate access to vaccines under Medicare (no specific legislation).
Rx drug importation into the U.S., other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Implementation of comparative effectiveness provisions of health care reform bill (H.R. 3590). Awareness and treatment of viral hepatitis (S. Res. 531; H.R. 3974). Expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization.
MERCK & CO INC via MERCK & CO, INC.
2010 · second_quarter · 2A
Deferral of taxation of foreign earned income and corporate taxation (no specific legislation). Renewal and expansion of the R&D tax credit (H.R. 422; S. 1203)
Change in formula for Average Manufacturers' Price for Medicaid. Efforts to amend the Medicare Modernization Act to impose government price controls on prescription drugs and to ensure appropriate access to vaccines under Medicare (no specific legislation).
End-use of derivatives (H.R. 4173)
MERCK & CO INC via MERCK & CO, INC.
2010 · second_quarter · Q2
Change in formula for Average Manufacturers' Price for Medicaid. Efforts to amend the Medicare Modernization Act to impose government price controls on prescription drugs and to ensure appropriate access to vaccines under Medicare (no specific legislation).
End-use of derivatives (H.R. 4173)
Deferral of taxation of foreign earned income and corporate taxation (no specific legislation). Renewal and expansion of the R&D tax credit (H.R. 422; S. 1203)
MERCK & CO INC via MERCK & CO, INC.
2010 · first_quarter · Q1
Deferral of taxation of foreign earned income and corporate taxation (no specific legislation). Renewal and expansion of the R&D tax credit (Support H.R. 422; S. 1203)
RX drug importation into the US, other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Promote public/private partnerships for comparative effectiveness assessment (S. 1213). Physician Payments Sunshine Act of 2009 (S. 301). Health care reform; increasing coverage of uninsured; coverage of preventative services, including immunizations; expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization; maintaining market-based, private sector health care delivery system. (H.R. 3200; S. 1679; S. 1796; H.R. 3590; H.R. 4872)
MERCK & CO INC via MERCK & CO, INC.
2009 · fourth_quarter · Q4
Oppose efforts to amend Medicare Modernization Act to impose government price controls on prescription drugs (no specific legislation). Support efforts to ensure appropriate access to vaccines under Medicare (HR 3200; S. 1796; H.R. 3590). Oppose expansion of or increase in Medicaid rebate (HR 3200; S.1796; H.R. 3590).
Issues related to deferral of taxation of foreign earned income and corporate taxation (no specific bill). Issues related to end use of derivatives (no specific bill). Support S. 1203, H.R. 422.
Oppose efforts to permit RX drug importation into U.S., other than by drug's manufacturer (no specific bill). Support efforts to require safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Support efforts to promote public/private partnerships for comparative effectiveness assessment (S.1213). Issues related to Physician Payments Sunshine Act of 2009 (S. 301). Issues related to health care reform; increasing coverage of uninsured; support efforts to gain coverage of preventive services, including immunizations; prevent 340B pricing expansion; maintaining market-based, private sector health care delivery system. (HR 3200; S. 1679; S. 1796; H.R. 3590)
MERCK & CO INC via MERCK & CO, INC.
2009 · third_quarter · Q3
Issues related to deferral of taxation of foreign earned income and corporate taxation (no specific bill). Issues related to end use of derivatives (no specific bill). Support S. 1203, H.R. 422.
Oppose efforts to amend Medicare Modernization Act to impose government price controls on prescription drugs (no specific legislation). Support efforts to ensure appropriate access to vaccines under Medicare (HR 3200; America's Healthy Futures Act of 2009). Oppose expansion of or increase in Medicaid rebate (HR 3200; American's Healthy Futures Act of 2009).
Oppose efforts to permit RX drug importation into U.S., other than by drug's manufacturer (no specific bill). Support efforts to require safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Support efforts to promote public/private partnerships for comparative effectiveness assessment (S.1213). Issues related to Physician Payments Sunshine Act of 2009 (S. 301). Issues related to health care reform; increasing coverage of uninsured; support efforts to gain coverage of preventive services, including immunizations; maintaining market-based, private sector health care delivery system. (HR 3200; S. 1679; America's Healthy Futures Act of 2009)
MERCK & CO INC via MERCK & CO, INC.
2009 · second_quarter · Q2
Oppose efforts to amend Medicare Modernization Act to impose government price controls on prescription drugs (no specific legislation). Support efforts to ensure appropriate access to vaccines under Medicare (no specific bill). Oppose expansion of or increase in Medicaid rebate (no specific bill).
Oppose efforts to permit RX drug importation into U.S., other than by drug's manufacturer (no specific bill). Support efforts to require safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Support efforts to promote public/private partnerships for comparative effectiveness assessment (S.1213). Issues related to Physician Payments Sunshine Act of 2009 (S. 301). Issues related to health care reform; increasing coverage of uninsured; maintaining market based, private sector health care delivery system. (no specific legislation)
MERCK & CO INC via MERCK & CO, INC.
2009 · first_quarter · Q1
Oppose efforts to amend Medicare Modernization Act to impose government price controls on prescription drugs (no specific legislation). Support efforts to ensure appropriate access to vaccines under Medicare (no specific bill). Oppose expansion of or increase in Medicaid rebate (no specific bill).
Issues related to deferral of taxation of foreign earned income.
Oppose efforts to permit RX drug importation into U.S., other than by drug's manufacturer (no specific bill). Support efforts to require safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Support efforts to promote public/private partnerships for comparative effectiveness assessment (no specific legislation). Issues related to Physician Payments Sunshine Act of 2009 (S. 301). Issues related to health care reform; increasing coverage of uninsured; maintaining market based, private sector health care delivery system. (no specific legislation)
MERCK & CO INC via MERCK & CO, INC.
2008 · fourth_quarter · Q4
Oppose efforts to permit RX drug importation into U.S., other than by drug's manufacturer (no specific bill). Support efforts to require safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Support efforts to promote public/private partnerships for comparative effectiveness assessment (no specific legislation). Issues related to Physician Payments Sunshine Act of 2007 (S. 2029)
Oppose efforts to amend Medicare Modernization Act to impose government price controls on prescription drugs (H.R. 4, S. 250). Support efforts to ensure appropriate access to vaccines under Medicare (no specific bill). Oppose expansion of or increase in Medicaid rebate (no specific bill).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2008 · third_quarter · Q3
Oppose efforts to permit RX drug importation into U.S., other than by drug's manufacturer (no specific bill). Support efforts to require safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Support efforts to promote public/private partnerships for comparative effectiveness assessment (no specific legislation). Support demonstration projects to assess the short-term and long-term effectiveness of obesity management programs (no specific bill). Support congressional interest in obesity awareness efforts (no specific bill). Issues related to Physician Payments Sunshine Act of 2007 (S. 2029).
Educate members of Congress, USTR on compulsory licenses in Thailand and Brazil (no specific legislation). Support intellectual property protections in trade negotiations (Columbia, Korea FTAs).
MERCK & CO INC via MERCK & CO, INC.
2008 · second_quarter · Q2
Oppose efforts to permit RX drug importation into U.S., other than by drug's manufacturer (no specific bill). Support efforts to require safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Support efforts to promote public/private partnerships for comparative effectiveness assessment (no specific legislation). Support demonstration projects to assess the short-term and long-term effectiveness of obesity management programs (no specific bill). Support congressional interest in obesity awareness efforts (no specific bill).
Oppose efforts to amend Medicare Modernization Act to impose government price controls on prescription drugs (H.R. 4, S. 250). Support efforts to ensure appropriate access to vaccines under Medicare (no specific bill). Oppose expansion of or increase in Medicaid rebate (no specific bill). Support coverage of preventive services in Medicare (H.R. 6331).
MERCK & CO INC via MERCK & CO, INC.
2008 · first_quarter · Q1
Oppose efforts to permit RX drug importation into U.S., other than by drug's manufacturer (no specific bill). Support efforts to require safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Support efforts to promote public/private partnerships for comparative effectiveness assessment (no specific legislation). Support demonstration projects to assess the short-term and long-term effectiveness of obesity management programs (no specific bill).
Oppose efforts to amend Medicare Modernization Act to impose government price controls on prescription drugs (H.R. 4, S. 250). Support efforts to ensure appropriate access to vaccines under Medicare (no specific bill). Oppose expansion of or increase in Medicaid rebate (no specific bill).
MERCK & CO INC via MERCK & CO, INC.
2007 · year_end · YY
Support amendments to patent reform legislation concerning post-grant review authority, apportionment of damages, venue and inequitable conduct provisions (S. 1145, H.R. 1908)
Oppose efforts to amend Medicare Modernization Act to impose government price controls on prescription drugs (H.R. 4, S. 250). Support efforts to ensure appropriate access to vaccines under Merdicare Part D (no specific bill). Oppose expansion of or increase in Medicaid rebate (no specific bill).
Oppose efforts to permit Rx drug importation into U.S., other than by drug's manufacturer. (No specific bill) Support efforts to require safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Support reauthorization of Prescription Drug User Fee Act and Better Pharmaceuticals for Children Act (S. 1080, H.R. 2900) Support efforts to promote public/private partnerships for comparative effectiveness assessment (no specific legislation).
MERCK & CO INC via MERCK & CO, INC.
2007 · mid_year · MM
Support amendments to Patent reform legislation concerning post-grant review authority, apportionment of damages and inequitable conduct provisions (S. 1145, H.R. 1908).
Support reauthorization of Prescription Drug User Fee Act and Better Pharmaceuticals for Children Act (S. 1080, H.R. 2900). Support efforts to promote public/private partnerships for health technology assessment (no specific legislation). Oppose efforts to permit Rx drug importation into U.S., other than by drug's manufacturer. (No specific bill) Support efforts to require safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill).
MERCK & CO INC via MERCK & CO, INC.
2006 · year_end · YY
Oppose efforts to permit Rx drug importation into U.S., other than by drug's manufacturer. (No specific bill) Support efforts to require safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill).
Support increased funding for CDC's National Immunization Program (Sec. 317 Program) (FY 2007 Labor-HHS Approprations bills)
Oppose efforts to amend Medicare Modernization Act to impose government price controls on prescription drugs (no specific bill) Support efforts to ensure appropriate access to vaccines under Medicare Part D (no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2006 · mid_year · MM
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MERCK & CO INC via MERCK & CO, INC.
2005 · year_end · YY
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MERCK & CO INC via MERCK & CO, INC.
2004 · year_end · YY
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
MERCK & CO INC via MERCK & CO, INC.
2003 · year_end · YY
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); additives in beef cattle (no specific bill); treatment of intellectual property in India
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Deficit reduction (no specific bill); ADAP funding (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Patent settlements (no specific bill)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill)
Deficit reduction (no specific bill); ADAP funding (no specific bill)
Supply chain safety (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); permanent normal trade relations with Russia (no specific bill); non-tariff trade barriers on U.S. beef (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Great Apes (S. 810)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); permanent normal trade relations with Russia (no specific bill); non-tariff trade barriers on U.S. beef (no specific bill)
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Prescription Drug User Fee Act (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); non-tariff trade barriers on U.S. beef
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of the R&D tax credit (H.R. 942; S 1577); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill).
Prescription Drug User Fee Act reauthorization (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); improvements to immunizations (no specific bills); health literacy (no specific bills); adherence (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Deficit Reduction (no specific bill); WTO Cotton Agreement (H.R. 2112)
Korea, Panama and Colombia Free Trade Agreements (no specifc bills); TransPacific Partnership
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of teh R&D tax credit (H.R. 942); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Korea, Colombia and Panama Free Trade Agreements (no specific bills); data exclusivity in free trade agrements (no specific bills)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of the R&D tax credit (H.R. 942); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Supplemental examination (S. 23)
Deficit reduction (no specific bill)
Korea, Colombia and Panama Free Trade Agreements (no specific bills); data exclusivity in free trade agrements (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Deferral of taxation of foreign earned income and corporate taxation (no specific legislation); renewal and expansion of the R&D tax credit (H.R. 422; S. 1203)
End use of derivatives (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Deferral of taxation of foreign earned income and corporate taxation (no specific legislation). Renewal and expansion of the R&D tax credit (H.R. 422; S. 1203)
Increased funding for CDC's National Immunization Program (Sec. 317 Program); increased funding for the AIDS Drug Assistance Program and for the Division of Viral Hepatitis at CDC (FY 11 Budget and Labor-Health & Human Services Appropriations bill; FY10 Supplemental Appropriations bill)
End-use of derivatives (H.R. 4173)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Increased funding for CDC's National Immunization Program (Sec. 317 Program); increased funding for the AIDS Drug Assistance Program and for the Division of Viral Hepatitis at CDC (FY 11 Budget and Labor-Health & Human Services Appropriations bill; FY10 Supplemental Appropriations bill)
Rx drug importation into the U.S., other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Implementation of comparative effectiveness provisions of health care reform bill (H.R. 3590). Awareness and treatment of viral hepatitis (S. Res. 531; H.R. 3974). Expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Rx drug importation into the U.S., other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Implementation of comparative effectiveness provisions of health care reform bill (H.R. 3590). Awareness and treatment of viral hepatitis (S. Res. 531; H.R. 3974). Expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization.
Increased funding for CDC's National Immunization Program (Sec. 317 Program); increased funding for the AIDS Drug Assistance Program and for the Division of Viral Hepatitis at CDC (FY 11 Budget and Labor-Health & Human Services Appropriations bill; FY10 Supplemental Appropriations bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Efforts to amend the Medicare Modernization Act to impose government price controls on prescription drugs (no specific legislation). Efforts to ensure appropriate access to vaccines under Medicare (H.R. 3200; S. 1796; H.R. 3590). Expansion of or increase in Medicaid rebate (H.R. 3200; S. 1796;H.R. 3590; H.R. 4872).
End use of derivatives (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Issues related to deferral of taxation of foreign earned income and corporate taxation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Oppose efforts to amend Medicare Modernization Act to impose government price controls on prescription drugs (H.R. 4, S. 250). Support efforts to ensure appropriate access to vaccines under Medicare (no specific bill). Oppose expansion of or increase in Medicaid rebate (no specific bill). Support coverage of preventive services in Medicare (H.R. 6331).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Educate members of Congress, USTR on compulsory licenses in Thailand and Brazil (no specific legislation). Support intellectual property protections in trade negotiations (Columbia, Korea FTAs).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Educate members of Congress on access to medicines and global intellectual property protection (no specific legislation).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Educate members of Congress, USTR, Commerce, State on compulsory licenses in Thailand and Brazil (no specific legislation). Support intellectual property protections in trade negotiations. (Peru FTA, Panama FTA, Columbia FTA, Korea FTA).
Support increased funding for CDC's National Immunization Program (Sec. 317 Program) (FY 2008 Labor-HHS Appropriations bills) Support increased funding for FDA (FY 2008 Agriculture Appropriations bills).
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Support increased funding for CDC's National Immunization Program (Sec. 317 Program) (FY 2008 Labor-HHS Appropriations bills) Support increased funding for FDA (FY 2008 Agriculture Appropriations bills).
Educate members of Congress, USTR, Commerce, State on compulsory licenses in Thailand and Brazil (no specific legislation). Support intellectual property protections in trade negotiations. (Peru FTS, Panama FTA, Coumbia FTA, Korea FTA).
Oppose efforts to amend Medicare Modernization Act to impose government price controls on prescription drugs (H.R. 4, S. 250). Support efforts to ensure appropriate access to vaccines under Medicare Part D (no specific bill). Oppose expansion of or increase in Medicaid rebate (no specific bill).
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Support efforts to add HPV vaccines to the list of taxable vaccines for purposes of the Vaccine Injury Compensation Trust Fund (H.R. 5495)
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office